6300 Dumbarton Circle
About Asterias Biotherapeutics
Asterias Biotherapeutics, Inc. is a biotechnology company pioneering the field of regenerative medicine. The company's proprietary cell therapy programs are based on its immunotherapy and pluripotent stem cell platform technologies. Asterias is presently focused on advancing three clinical-stage programs which have the potential to address areas of very high unmet medical need in the fields of neurology and oncology. AST-OPC1 (oligodendrocyte progenitor cells) is currently in a Phase 1/2a dose escalation clinical trial in spinal cord injury.
Stock Symbol: AST
Stock Exchange: NYSE
In 2016, Lucas Lindner was in a car accident that left him paralyzed from the neck down. Lindner was enrolled in a clinical trial at the Medical College of Wisconsin and was operated on at Froedtert Hospital in Milwaukee. He received 10 million AST-OPC1 cells injected into the injured area of his spinal cord. These cells have helped Lindner regain function in his arms, hands and fingers. He was the third patient in the world to receive the cells developed by Asterias Biotherapeutics. This is his story.
137 articles about Asterias Biotherapeutics
Aspen Neuroscience closed on a Series B funding round of $147.5 million. The company is focused on developing personalized cell replacements for Parkinson’s disease.
Plenty of biotech companies will be releasing their third-quarter financial reports next week. Let’s take a quick look at some of these companies and their top stories they reported through 3Q2018.
BioTime and Asterias Biotherapeutics Enter Into Definitive Merger Agreement to Create Leading Cell Therapy Company
BioTime Acquires Two Clinical-Stage Cell Therapy Product Candidates Addressing Significant Unmet Needs in Spinal Cord Injury and Immuno-Oncology
Shares of Asterias Biotherapeutics have soared nearly 30 percent in premarket trading after it was announced that the Fremont, Calif.-based company was being absorbed by BioTime, Inc. in an attempt to create a leading cell therapy company.
11/5/2018Biopharma companies make key appointments to fill leadership positions. Let's take a look!
BioTime, Inc. today announced that it will release second quarter 2018 financial and operating results on Thursday, August 2, 2018, after the close of the U.S. financial markets.
AgeX Therapeutics, Inc. today announced that it has closed a $5 million equity financing, through the sale of two million AgeX common shares to Juvenescence Ltd.
BioTime, Inc., has been awarded a new grant for 2018 of up to 6.9 million Israeli New Shekels (approximately $1.9 million) from the Israel Innovation Authority (the “IIA”).
Asterias Expands Global IP Portfolio With New Patents, Including Key Additional Patent Protection for its Cancer Immunotherapy Program
Of the 46 patents, 38 are owned or jointly owned by Asterias and eight patents are exclusively licensed to the Company.
These achievements, combined with the Company’s financial resources position Asterias to achieve the following milestones during 2018.
The Company has enrolled a total of 25 subjects in the SCiStar study, plus five subjects from a previous Phase 1 safety trial.
As of September 30, 2017, the combined total of cash, cash equivalents, and available-for-sale securities totaled $20.7 million.
The Company will host a conference call and webcast on November 14, 2017 at 4:30 p.m. Eastern / 1:30 p.m.
Asterias intends to use the net proceeds from this offering for clinical trial and process development activities related to its AST-OPC1 .
The offering is expected to close on or about October 18, 2017, subject to the satisfaction of customary closing conditions.
Asterias Biotherapeutics’ AST-OPC1 Clinical Trial Will Continue As Planned Following Recommendation Of Data Monitoring Committee
Preclinical Data Published In Peer-Reviewed Journal Stem Cells Translational Medicine Provides Scientific Framework For Asterias Biotherapeutics’ AST-OPC1 For The Treatment Of Subacute Cervical Spinal Cord Injury
Asterias Biotherapeutics Reports Second Quarter Financial Results And Reviews Recent Clinical Progress And Corporate Developments